PRODUCTION OF MHC II/CII COMPLEXES
Registre | Brevet WIPO |
---|---|
Numéro d'application | EP2020072287 |
Numéro de publication | 2021/028350 |
Statut | Délivré - en vigueur |
Date de dépôt | 2020-08-07 |
Date de publication | 2021-02-18 |
Propriétaire | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Allemagne) |
Inventeur(s) |
|
Abrégé
[142] The present invention relates to in situ glycosylated MHC II/CII peptide complexes, i.e., complexes naturally glycosylated during recombinant protein expression in the host cell. The invention further relates to methods of producing glycosylated MHC II/CII peptide complexes in mammalian cells. Furthermore the invention relates to the use of such post-translationally modified, preferably glycosylated MHC/CII complexed for use in treating rheumatoid arthritis, preferably in humans.Classes IPC ?
- A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
- A61P 37/00 - Drugs for immunological or allergic disorders